Love the management comments and sure sounds like
Post# of 72440
(Total Views: 244)
Posted On: 09/24/2018 9:22:45 AM
Love the management comments and sure sounds like IPIX is following the REGN model to me.
Management Comments
“We have analyzed the full dataset from our Phase 2 study, versus other publicly available datasets from comparable studies, and believe Brilacidin stands apart from the competition in reducing the incidence of SOM in this patient population,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer of Innovation Pharmaceuticals. “We, along with potential pharmaceutical industry partners, are excited that SOM incidence reduction is an achievable outcome. Significantly reducing incidence of SOM obviously provides the greatest therapeutic benefit to patients, rather than merely decreasing symptoms, as is the case with today’s limited palliative-only OM therapies.”
“In aggregate, the data from the Brilacidin Phase 2 study was impressive and we will consider expanding the drug to other cancer indications in the future,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “For now, we want to maintain our focus on the shortest path to commercialization, which we believe is best achieved by targeting treatment in the more aggressive chemotherapy regimens, in which cases of severe oral mucositis abound.”
Go IPIX!!!
Management Comments
“We have analyzed the full dataset from our Phase 2 study, versus other publicly available datasets from comparable studies, and believe Brilacidin stands apart from the competition in reducing the incidence of SOM in this patient population,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer of Innovation Pharmaceuticals. “We, along with potential pharmaceutical industry partners, are excited that SOM incidence reduction is an achievable outcome. Significantly reducing incidence of SOM obviously provides the greatest therapeutic benefit to patients, rather than merely decreasing symptoms, as is the case with today’s limited palliative-only OM therapies.”
“In aggregate, the data from the Brilacidin Phase 2 study was impressive and we will consider expanding the drug to other cancer indications in the future,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “For now, we want to maintain our focus on the shortest path to commercialization, which we believe is best achieved by targeting treatment in the more aggressive chemotherapy regimens, in which cases of severe oral mucositis abound.”
Go IPIX!!!
(2)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼